Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

BACKGROUND: In the prepertuzumab era, we evaluated the clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who underwent first-line trastuzumab-based or lapatinib-based therapy according to prior exposure to (neo)adjuvant trastuzumab....

Descripción completa

Detalles Bibliográficos
Autores principales: Blondeaux, Eva, Ferreira, Arlindo R, Poggio, Francesca, Puglisi, Fabio, Bighin, Claudia, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Lai, Antonella, Sini, Valentina, Minuti, Gabriele, Mura, Silvia, Fontana, Andrea, Fregatti, Piero, Cardinali, Barbara, Lambertini, Matteo, Del Mastro, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437709/
https://www.ncbi.nlm.nih.gov/pubmed/32817059
http://dx.doi.org/10.1136/esmoopen-2020-000719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437709/
https://www.ncbi.nlm.nih.gov/pubmed/32817059
http://dx.doi.org/10.1136/esmoopen-2020-000719

Ejemplares similares